moneyheap
AMRX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) stock moving?
Amneal reported Q3 2026 results on Nov 3 that beat consensus on both lines: adjusted EPS of $0.26 versus a $0.23 estimate, and sales of $862.7M versus $816.1M. Revenue grew 10% year over year, Affordable Medicines rose 19% and Specialty rose 20%, while AvKARE fell 17% as expected. Management raised 2026 guidance for net revenue to $3.150B-$3.250B and adjusted EPS to $1.04-$1.08, both above the prior ranges and the $1.03 EPS consensus. Weak points are a GAAP net loss of $22M, driven by acquisition and integration costs tied to Kashiv, and a higher share count. Sell-side reaction was supportive: JP Morgan lifted its target to $25, Leerink to $25 and UBS to $28, all keeping positive ratings. The share price did not follow the beat right away. It slipped from $21.51 on Oct 30 to $20.21 on Nov 3 and $19.45 on Nov 5, on heavy volume of 6.4M and 7.2M shares on Nov 3 and Nov 4. It then recovered to $21.38 on Nov 10, close to the $21.68 high of Oct 30, with volume easing to 2.4M. The stock has recovered most of the post-earnings drop, but it is still below its late-October level.
News behind the analysis
- Amneal Pharmaceuticals Named Top Large Employer in BioSpace 2027 Best Places to Work ListBioSpace ranked Amneal as the number one large employer in the biopharmaceutical industry in its 2027 Best Places to Work list. This is a reputational item with no direct financial impact.
- UBS Raises Amneal Pharmaceuticals Price Target to $28UBS raised its price target from $25 to $28 and kept a Buy rating on the stock.
- Leerink Partners Maintains Outperform on Amneal Pharmaceuticals, Raises Price Target to $25Leerink Partners kept its Outperform rating and raised its price target to $25 after the quarterly results.
- JP Morgan Raises Amneal Pharmaceuticals Price Target to $25JP Morgan maintained its Overweight rating and raised its price target from $24 to $25.
- JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25JP Morgan kept its Overweight rating on Amneal and lifted its price target to $25 following the Q3 report.
- Amneal Pharmaceuticals Reports Third Quarter 2026 Financial Results and Raises Full-Year GuidanceQ3 2026 net revenue reached $863 million, and the company raised full-year 2026 guidance. GAAP net loss was $22 million, while adjusted EBITDA rose 30% to $207 million.
- Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 Est; Raises FY2026 Sales Guidance from $3.100B-$3.200B to $3.150B-$3.250B vs $3.159B EstAdjusted EPS guidance was raised to $1.04-$1.08 from $0.96-$1.06, above the $1.03 consensus. Sales guidance was raised to $3.150B-$3.250B from $3.100B-$3.200B, versus a $3.159B estimate.
- Amneal Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.23 Estimate, Sales $862.684M Beat $816.058M EstimateQ3 adjusted EPS of $0.26 beat the $0.23 estimate, and sales of $862.684M beat the $816.058M estimate. Revenue rose 10% year over year.
- Amneal Pharmaceuticals Q3 2026 Earnings Call TranscriptManagement discussed Q3 2026 results, the Kashiv integration, and new launches including biosimilars, lanreotide, CREXONT and the BREKIYA autoinjector. Co-CEOs said they remain highly confident in the growth outlook.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals is a New Jersey-based drugmaker, founded in 2002 by brothers Chirag and Chintu Patel, who are still its co-CEOs. It mostly sells generic medicines, including complex generics and injectables. It also has a growing line of specialty brands, such as CREXONT for Parkinson's disease and the BREKIYA autoinjector, and it added biosimilars through its acquisition of Kashiv, which closed in August 2026.
How it makes money
Most of Amneal's revenue comes from its Affordable Medicines segment, which sells generic drugs, including complex generics, injectables and biosimilars, to US wholesalers and pharmacies. The rest comes from Specialty, which sells branded drugs mainly for neurology and migraine, and from AvKARE, a private-label distributor that supplies US government agencies. Total revenue was roughly $3.0 billion in 2025, and the company's 2026 guidance is about $3.15–3.25 billion.
What usually moves AMRX
- New generic, injectable and biosimilar launches
- Sales growth of specialty brands like CREXONT
- Generic drug pricing pressure and FDA approvals
- Debt levels and interest costs
- Manufacturing and supply disruptions